Collaborative Multi-institutional Experience in Comparing PD-L1 Immunohistochemistry Assays: Concordance of SP142 and 22C3 Immunoreactivity

被引：3
|
作者：
Karim, Lina Abdul [1 ]
Kallakury, Bhaskar V. S. [1 ]
Chahine, Joeffrey J. [1 ]
Sheehan, Christine E. [2 ]
Ross, Jeffrey S. [2 ,3 ]
机构：
[1] Medstar Georgetown Univ Hosp NW, Dept Pathol & Lab Med, Washington, DC 20057 USA
[2] Albany Med Coll, Dept Pathol, Albany, NY 12208 USA
[3] Fdn Med Inc, Cambridge, MA USA
来源：
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2018年 / 26卷 / 02期
关键词：
D O I：
10.1097/PAI.0000000000000609
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
引用
收藏
页码：E22 / E22
页数：1
相关论文
共 50 条
  • [1] Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
    Haipeng Xu
    Gen Lin
    Cheng Huang
    Weifeng Zhu
    Qian Miao
    Xirong Fan
    Biao Wu
    Xiaobing Zheng
    Xiandong Lin
    Kan Jiang
    Dan Hu
    Chao Li
    Scientific Reports, 7
  • [2] Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer
    Xu, Haipeng
    Lin, Gen
    Huang, Cheng
    Zhu, Weifeng
    Miao, Qian
    Fan, Xirong
    Wu, Biao
    Zheng, Xiaobing
    Lin, Xiandong
    Jiang, Kan
    Hu, Dan
    Li, Chao
    SCIENTIFIC REPORTS, 2017, 7
  • [3] PD-L1 Testing in Urothelial Carcinoma: Analysis of a Series of 1401 Cases Using Both the 22C3 and SP142 Assays
    Evans, Harriet
    O'Sullivan, Brendan
    Hughes, Frances
    Charles, Kathryn
    Robertson, Lee
    Taniere, Philippe
    Diaz-Cano, Salvador
    PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28
  • [4] Assessment of concordance among 22C3, SP263, and SP142 immunohistochemistry assay for PD-L1 expression in non-small cell lung cancer.
    Jung, Chi Young
    Kim, Eun Jin
    Sung, Woo Jung
    CANCER IMMUNOLOGY RESEARCH, 2020, 8 (04) : 41 - 42
  • [5] Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer
    Miyakoshi, Jun
    Yazaki, Shu
    Shimoi, Tatsunori
    Onishi, Mai
    Saito, Ayumi
    Kita, Shosuke
    Yamamoto, Kasumi
    Kojima, Yuki
    Sumiyoshi-Okuma, Hitomi
    Nishikawa, Tadaaki
    Sudo, Kazuki
    Noguchi, Emi
    Murata, Takeshi
    Shiino, Sho
    Takayama, Shin
    Suto, Akihiko
    Fujiwara, Yasuhiro
    Yoshida, Masayuki
    Yonemori, Kan
    VIRCHOWS ARCHIV, 2023, 483 (06) : 855 - 863
  • [6] Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer
    Jun Miyakoshi
    Shu Yazaki
    Tatsunori Shimoi
    Mai Onishi
    Ayumi Saito
    Shosuke Kita
    Kasumi Yamamoto
    Yuki Kojima
    Hitomi Sumiyoshi-Okuma
    Tadaaki Nishikawa
    Kazuki Sudo
    Emi Noguchi
    Takeshi Murata
    Sho Shiino
    Shin Takayama
    Akihiko Suto
    Yasuhiro Fujiwara
    Masayuki Yoshida
    Kan Yonemori
    Virchows Archiv, 2023, 483 : 855 - 863
  • [7] PD-L1 status in Taiwanese lung adenocarcinoma patients: Comparison of PD-L1 immunohistochemical assays using antibody clones 22C3, SP142 and SP263 with clinicopathological correlation
    Yeh, Y-C.
    Lin, S-F.
    Chiu, C-H.
    Wu, Y-C.
    Hsieh, W-Y.
    Ho, H-L.
    Chou, T-Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] PD-L1 immunohistochemical expression in bladder urothelial cancer with SP263, SP142 and 22C3 antibodies: A comparative study
    Paliogiannis, Panagiotis
    Lobrano, Renato
    Bella, Michele Angelo
    Fara, Antonella
    Uras, Maria Gabriela
    Pinna, Maria Antonia
    Tedde, Alessandro
    Madonia, Massimo
    Zinellu, Angelo
    Cossu, Antonio
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 69
  • [9] PD-L1 (SP142 and 22C3) immunohistochemistry in clinical metastatic triple-negative or low hormone receptor breast carcinomas: experience from a large academic institution
    Shafi, Saba
    Parwani, Anil V.
    Li, Zaibo
    HUMAN PATHOLOGY, 2022, 126 : 100 - 107
  • [10] Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial
    Gadgeel, Shirish
    Hirsch, Fred R.
    Kerr, Keith
    Barlesi, Fabrice
    Park, Keunchil
    Rittmeyer, Achim
    Zou, Wei
    Bhatia, Namrata
    Koeppen, Hartmut
    Paul, Sarah M.
    Shames, David
    Yi, Jing
    Matheny, Christina
    Ballinger, Marcus
    McCleland, Mark
    Gandara, David R.
    CLINICAL LUNG CANCER, 2022, 23 (01) : 21 - 33
12345